Results 41 to 50 of about 18,311 (150)
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages.
Immunity, 2023 M. Tichet, S. Wullschleger, Agnieszka Chryplewicz, Nadine Fournier, R. Marcone, Annamaria Kauzlaric, K. Homicsko, Laura Codarri Deak, P. Umaña, Christian Klein, D. Hanahan +10 moresemanticscholar +1 more sourceImmunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer
EBioMedicine, 2023 F. Ghiringhelli, F. Bibeau, L. Greillier, J. Fumet, A. Ilie, F. Monville, Caroline Laugé, A. Catteau, I. Boquet, Amine Majdi, Erwan Morgand, Y. Oulkhouir, Nicolas Brandone, J. Adam, T. Sbarrato, A. Kassambara, J. Fieschi, Stéphane Garcia, A. Lepage, P. Tomasini, J. Galon +20 moresemanticscholar +1 more source